Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Graham, J. Punt, M. Arora, R. Day, M. Doogue, J. Duong, T. Furlong, J. Greenfield, L. Greenup, C. Kirkpatrick, J. Ray, P. Timmins, K. Williams (2011)
Clinical Pharmacokinetics of MetforminClinical Pharmacokinetics, 50
Zakikhani (2006)
Metformin is anAMPkinase-dependent growth inhibitor for breast cancer cellsCancer Research [Internet], 66
O. Arrieta, F. Barrón, M. Padilla, A. Avilés-Salas, L. Ramírez-Tirado, Manuel Jiménez, E. Vergara, Z. Zatarain-Barrón, N. Hernández-Pedro, A. Cardona, G. Cruz-Rico, P. Barrios-Bernal, Masao Ramos, R. Rosell (2019)
Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial.JAMA oncology
G. Rena, D. Hardie, E. Pearson (2017)
The mechanisms of action of metforminDiabetologia, 60
M. Rieken, E. Xylinas, L. Kluth, J. Crivelli, J. Chrystal, T. Faison, Y. Lotan, P. Karakiewicz, M. Sun, H. Fajkovic, M. Babjuk, A. Bachmann, D. Scherr, S. Shariat (2014)
Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.Urologic oncology, 32 1
L. Lévesque, J. Hanley, A. Kezouh, S. Suissa (2010)
Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetesBMJ : British Medical Journal, 340
H. Noto, A. Goto, T. Tsujimoto, Mitsuhiko Noda (2012)
Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysisPLoS ONE, 7
M. Goossens, F. Buntinx, M. Zeegers, Annemariek Driessen, M. Bruin, F. Vries (2015)
Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patientsArchives of Public Health, 73
Wei-lun Huang, Kuo-How Huang, Chao-yuan Huang, Y. Pu, Hong-Chiang Chang, Po-Ming Chow (2020)
Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective studyBMC Urology, 20
M. Tuccori, K. Filion, H. Yin, O. Yu, R. Platt, L. Azoulay (2016)
Pioglitazone use and risk of bladder cancer: population based cohort studyThe BMJ, 352
S. Oliveria, C. Koro, M. Yood, M. Sowell (2008)
Cancer incidence among patients treated with antidiabetic pharmacotherapyDiabetes and Metabolic Syndrome: Clinical Research and Reviews, 2
C. Tseng (2011)
Diabetes and risk of bladder cancer: a study using the National Health Insurance database in TaiwanDiabetologia, 54
T. Lyon, I. Frank, Paras Shah, R. Tarrell, J. Cheville, J. Karnes, H. Thompson, M. Tollefson, S. Boorjian (2018)
The Association of Aspirin Use with Survival Following Radical CystectomyThe Journal of Urology, 200
B. Oresta, C. Pozzi, D. Braga, R. Hurle, M. Lazzeri, P. Colombo, N. Frego, M. Erreni, C. Faccani, G. Elefante, M. Barcella, G. Guazzoni, M. Rescigno (2021)
Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancerScience Translational Medicine, 13
B. Heckman-Stoddard, A. Decensi, V. Sahasrabuddhe, L. Ford (2017)
Repurposing metformin for the prevention of cancer and cancer recurrenceDiabetologia, 60
Steven Kahn, S. Haffner, M. Heise, William Herman, Rury Holman, Nigel Jones, B. Kravitz, J. Lachin, M. O'neill, B. Zinman, G. Viberti (2006)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.The New England journal of medicine, 355 23
Zhongbo Liu, N. Yokoyama, Christopher Blair, Xuesen Li, D. Avizonis, Xue-Ru Wu, E. Uchio, R. Youssef, Michael McClelland, M. Pollak, X. Zi (2016)
High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than SerumMolecular Cancer Therapeutics, 15
Huilin Tang, Weilong Shi, Shuangshuang Fu, Tiansheng Wang, S. Zhai, Yiqing Song, Jiali Han (2018)
Pioglitazone and bladder cancer risk: a systematic review and meta‐analysisCancer Medicine, 7
A. Decensi, M. Puntoni, P. Goodwin, M. Cazzaniga, A. Gennari, B. Bonanni, S. Gandini (2010)
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysisCancer Prevention Research, 3
J. Tierney, L. Stewart, D. Ghersi, S. Burdett, M. Sydes (2007)
Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 8
(2016)
Impact ofglycemic control and metformin use on the recurrence andprogression of non-muscle invasive bladdercancer in patients with diabetes mellitus
C. Tseng (2014)
Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetesActa Diabetologica, 51
Remco Molenaar, Jons Hattum, I. Brummelhuis, J. Oddens, C. Savci-Heijink, E. Boevé, Saskia Meer, J. Witjes, Michael Pollak, Michael Pollak, T. Reijke, J. Wilmink (2019)
Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancerBMC Cancer, 19
Yu Wang, Hongying An, Ting Liu, Caolitao Qin, H. Sesaki, Shaodong Guo, S. Radovick, M. Hussain, A. Maheshwari, F. Wondisford, B. O’Rourke, Ling He (2019)
Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPKCell reports, 29
R. Sylvester, Ó. Rodríguez, V. Hernández, D. Turturica, L. Bauerová, H. Bruins, J. Bründl, T. Kwast, A. Brisuda, J. Rubio-Briones, M. Seles, A. Hentschel, V.R.M. Kusuma, N. Huebner, J. Cotte, L. Mertens, D. Volanis, O. Cussenot, J. Henríquez, E. Peña, F. Pisano, M. Pešl, A. Heijden, Sonja Herdegen, A. Zlotta, J. Hacek, A. Calatrava, S. Mannweiler, J. Bosschieter, D. Ashabere, A. Haitel, J. Côté, Soha Sheikh, L. Lunelli, F. Algaba, I. Alemany, F. Soria, Willemien Runneboom, J. Breyer, J. Nieuwenhuijzen, C. Llorente, L. Molinaro, C. Kaa, M. Evert, L. Kiemeney, J. N'Dow, K. Plass, O. Čapoun, V. Soukup, J. Dominguez-escrig, D. Cohen, J. Palou, P. Gontero, M. Burger, R. Zigeuner, A. Mostafid, S. Shariat, M. Rouprêt, E. Compérat, M. Babjuk, B. Rhijn (2021)
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.European urology
Youngjoo Lee, J. Joo, You Lee, E. Lee, Sohyun Park, Tae-sung Kim, Soo-Hyun Lee, S. Kim, G. Wie, Minjoung Park, Mi-Jung Kim, J. Lee, Ji-Youn Han (2020)
Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer.Lung cancer, 151
R. Mamtani, N. Pfanzelter, K. Haynes, B. Finkelman, Xingmei Wang, S. Keefe, N. Haas, D. Vaughn, J. Lewis (2014)
Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or SulfonylureasDiabetes Care, 37
K. Marrone, Xian Zhou, P. Forde, M. Purtell, J. Brahmer, C. Hann, R. Kelly, B. Coleman, E. Gabrielson, G. Rosner, D. Ettinger (2018)
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung CancerThe Oncologist, 23
R. Dankner, Nirit Agay, L. Olmer, Havi Murad, Lital Boker, R. Balicer, L. Freedman (2019)
Metformin Treatment and Cancer Risk: Cox Regression Analysis, With Time-Dependent Covariates, of 320,000 Persons With Incident Diabetes MellitusAmerican Journal of Epidemiology, 188
Mei Peng, Qiongli Su, Q. Zeng, Le Li, Zhihong Liu, Lei Xue, Yan Cheng, Yanjun Huang, Ting Tao, H. Lv, Xiao-hui Li, Xiaojun Tao, P. Guo, Alex Chen, Xiaoping Yang (2016)
High efficacy of intravesical treatment of metformin on bladder cancer in preclinical modelOncotarget, 7
K. Tsilidis, Despoina Capothanassi, N. Allen, E. Rizos, D. Lopez, K. Veldhoven, C. Sacerdote, D. Ashby, P. Vineis, I. Tzoulaki, J. Ioannidis (2014)
Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat TrialDiabetes Care, 37
Rana Sayed, A. Saad, L. Wakeel, E. Elkholy, O. Badary (2015)
Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study.Asian Pacific journal of cancer prevention : APJCP, 16 15
Yu-Ching Chen, V. Kok, Ching-Hsuan Chien, Jorng-Tzong Horng, J. Tsai (2015)
Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparatorTherapeutics and Clinical Risk Management, 11
M. Rieken, E. Xylinas, L. Kluth, J. Crivelli, J. Chrystal, T. Faison, Y. Lotan, P. Karakiewicz, H. Fajkovic, M. Babjuk, A. Kautzky-Willer, A. Bachmann, D. Scherr, S. Shariat (2013)
Association of diabetes mellitus and metformin use with oncological outcomes of patients with non‐muscle‐invasive bladder cancerBJU International, 112
A. Neumann, Alain Weill, P. Ricordeau, J. Fagot, F. Alla, H. Allemand (2012)
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort studyDiabetologia, 55
M. Zakikhani, R. Dowling, I. Fantus, N. Sonenberg, M. Pollak (2006)
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.Cancer research, 66 21
Mei Peng, Yanjun Huang, Ting Tao, Cai-Yun Peng, Qiongli Su, Wanjun Xu, K. Darko, Xiaojun Tao, Xiaoping Yang (2016)
Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and ErkScientific Reports, 6
A. Vancura, P. Bu, M. Bhagwat, Joey Zeng, I. Vancurova (2018)
Metformin as an Anticancer Agent.Trends in pharmacological sciences, 39 10
K. Sievert, Bastian Amend, U. Nagele, D. Schilling, Jens Bedke, M. Horstmann, J. Hennenlotter, S. Kruck, A. Stenzl (2009)
Economic aspects of bladder cancer: what are the benefits and costs?World Journal of Urology, 27
Goossens (2015)
Influence of metformin intake on the risk of bladder cancerin type 2 diabetes patientsBritish Journal of ClinicalPharmacology, 80
F. Neto, S. Bernardes, P. Marinello, G. Melo, R. Luiz, R. Cecchini, A. Cecchini (2017)
Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanomaMelanoma Research, 27
F. Heidari, Shahin Zade, Seyed Hosseini, A. Ghadian (2016)
Metformin for the Prevention of Bladder Cancer Recurrence: Is it Effective?Nephro-urology Monthly, 8
A. Hendriks, D. Schrijnders, N. Kleefstra, E. Vries, H. Bilo, M. Jalving, G. Landman (2019)
Sulfonylurea derivatives and cancer, friend or foe?European journal of pharmacology
P. Richard, Ardalan Ahmad, Shaheena Bashir, A. Zlotta, B. Bhindi, R. Leão, M. Nayan, Aza Mohammed, N. Fleshner, G. Kulkarni (2018)
Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis.Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 12 6
Dong Wang, Xiao-hou Wu (2015)
In vitro and in vivo targeting of bladder carcinoma with metformin in combination with cisplatin.Oncology letters, 10 2
M. Page, J. McKenzie, P. Bossuyt, I. Boutron, T. Hoffmann, C. Mulrow, Larissa Shamseer, J. Tetzlaff, E. Akl, S. Brennan, R. Chou, Julie Glanville, J. Grimshaw, A. Hrõbjartsson, M. Lalu, Tianjing Li, E. Loder, E. Mayo-Wilson, Steve McDonald, L. McGuinness, L. Stewart, James Thomas, A. Tricco, V. Welch, P. Whiting, D. Moher (2020)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsSystematic Reviews, 10
F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, Lindsey Torre, A. Jemal (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 68
P. Home, S. Pocock, H. Beck-Nielsen, P. Curtis, R. Gomis, M. Hanefeld, N. Jones, M. Komajda, J. McMurray (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialThe Lancet, 373
Lévesque (2010)
Problem of immortal time bias in cohort studies: Example using statins for preventing progression of diabetesBMJ (Online) [Internet], 340
J. Sung, Jason Ho, A. Lam, S. Yau, K. Tsoi (2020)
Use of metformin and aspirin is associated with delayed cancer incidence.Cancer epidemiology, 69
S. Kordes, M. Pollak, A. Zwinderman, R. Mathôt, M. Weterman, A. Beeker, C. Punt, D. Richel, J. Wilmink (2015)
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.The Lancet. Oncology, 16 7
M. Nayan, B. Bhindi, Julie Yu, T. Hermanns, Aza Mohammed, R. Hamilton, A. Finelli, M. Jewett, A. Zlotta, N. Fleshner, G. Kulkarni (2015)
The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder.Urologic oncology, 33 9
H. Murff, C. Roumie, R. Greevy, A. Hackstadt, L. McGowan, A. Hung, Carlos Grijalva, M. Griffin (2018)
Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancerCancer Causes & Control, 29
BACKGROUND:Effective oral treatment options for urothelial bladder cancer (BC) are lacking. Metformin, the most frequently used oral drug in type II diabetes mellitus, has putative anticancer properties and could, therefore, influence BC incidence and treatment outcomes. We systematically reviewed the current literature regarding the effect of metformin on BC incidence and oncological outcomes in non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC).METHODS:This review was conducted according to the PRISMA guidelines. Literature was gathered through a systematic search in PubMed/Medline, EMBASE and the Cochrane library. Risk of bias was determined using the Cochrane risk-of-bias tool for randomized trials and the Newcastle-Ottawa Scale for non-randomized trials. Hazard ratios (HRs) were extracted and pooled in a random-effects meta-analysis.RESULTS:We reviewed 13 studies, including 3,315,320 patients, considering the risk of developing BC after metformin exposure and 9 studies, including 4,006 patients, on oncological outcomes of patients with BC. Metformin did not affect BC incidence (HR 0.97, 95% CI 0.87 –1.09) or oncological outcomes for NMIBC but did show a reduced risk of recurrence (HR 0.52, 95% CI 0.32 –0.84), cancer-specific mortality (HR 0.58, 95% CI 0.43 –0.78) and overall mortality (HR 0.66, 95% CI 0.47 –0.92) in MIBC.CONCLUSIONS:The role of metformin in the prevention and treatment of BC in patients remains unclear. Although a beneficial effect of metformin on treatment outcomes of certain stages of BC may exist, a definitive conclusion cannot be drawn. Prospective clinical trials are needed to assess the efficacy of metformin for BC treatment.
Bladder Cancer – IOS Press
Published: Jun 3, 2022
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.